Affiliation:
1. Shaoxing Central Hospital
Abstract
Abstract
Background: Intracranial atherosclerotic stenosis (ICAS) is one of the important causes of occurrence and recurrence of ischemic stroke worldwide. Combined antiplatelet therapy may increase the risk of intracerebral hemorrhage, especially in patients with intracerebral microhemorrhage,Objective The aim of this study is to investigate the safety of dual antiplatelet drugs in patients with symptomatic intracranial atherosclerotic stenosis (sICAS) and cerebral microbleeds(CMBs).
Methods and Results: 305 patients with sICAS were divided into two groups: 215 patients without CMBs and 90 patients with CMBs. All patients were treated with dual antibody therapy for 3 months according to the existing treatment, and were followed up for half a year. The NIHSS and modified Rankin score (mRS) before and after treatment were compared between the two groups, and the incidence of adverse reactions and bleeding conversion were observed. At the same time, the two groups were compared. Moderate to severe CMBs (>6) increased the risk of bleeding in sICAS.
Conclusion For patients with sICAS, it is necessary to conduct head MRI SWI sequence examination to screen out high load CMBs.
Publisher
Research Square Platform LLC
Reference18 articles.
1. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis[J];Chimowitz MI;N Engl J Med,2005
2. Wong KS, Chen C, Fu J et al.Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients
3. with acute symptomatic. cerebral or carotid artery stenosis (CLAIR study): a randomised, openlabel, blinded
4. endpoint trial[J]. Lancet Neurol. 2010;9(5):489–97. 10.1016/S1474-4422(10)70060-0.
5. Markus HS, Droste DW, Kaps M et al.Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic